title: Antipsychotic drugs and QT interval prolongation.
abstract: The QTc prolongation by antipsychotic drugs is of major concern, especially in light of the data indicating an increased risk of sudden death in psychiatric patients taking these drugs. Sudden death in psychiatric patients could be partially attributed to drug-induced torsades de pointes and for this reason careful evaluation of QTc prolonging properties of antipsychotic drugs is needed. Antipsychotic drugs prolong QT interval usually by blocking the potassium IKr current. Improved understanding of ion channel structure and kinetics and its role in repolarization has tremendous impact on understanding of the mechanisms of drug-induced QT prolongation and torsades de pointes. Proarrhythmia caused by a QT-prolonging drug occurs infrequently, and usually multiple factors need to operate to precipitate such an event including a combination of two or more drugs affecting the same pathway, hypokalemia, and possibly genetic predisposition. Currently prescribed antipsychotics might cause QT prolongation ranging from 4-6 ms for haloperidol and olanzapine to 35 ms for thioridazine. The response of a patient to a drug is very individual and therefore an individualized system of drug administration and monitoring needs to be developed which takes into account baseline QTc duration and its changes after a drug was introduced. A systematic approach while stratifying psychiatric patients as those with short QTc (QTc < or = 0.41 sec), borderline QTc (QTC = 0.42-0.44 sec), and prolonged QTc (0.45 sec) is being proposed to improve the safety of administering antipsychotic drugs and to decrease the risk of drug-related sudden death in psychiatric patients.
authors.affiliation: Cardiology Unit, Department of Medicine, University of Rochester Medical Center, Rochester, NY 14642, USA. wojciech_zareba@urmc.rochester.edu
authors.forename: Wojciech
authors.initials: W
authors.lastname: Zareba
authors.forename: David A
authors.initials: DA
authors.lastname: Lin
mesh_terms: D000367:Age Factors; D000465:Algorithms; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001569:Benzodiazepines; D016757:Death, Sudden, Cardiac / Q000209:etiology; D018492:Dopamine Antagonists / Q000009:adverse effects; D004348:Drug Labeling; D006220:Haloperidol / Q000009:adverse effects*; D006801:Humans; D008133:Long QT Syndrome / Q000139:chemically induced* / Q000517:prevention & control; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects / Q000031:analogs & derivatives*; D012737:Sex Factors; D013881:Thioridazine / Q000009:adverse effects; D016171:Torsades de Pointes / Q000139:chemically induced
chemical_list: D014150:Antipsychotic Agents; D018492:Dopamine Antagonists; D001569:Benzodiazepines; D010890:Pirenzepine; D006220:Haloperidol; D013881:Thioridazine; D000077152:Olanzapine